GLP-1 Brand Diversification: How to Pivot Into Other DTC Rx Verticals Before Compounded Semaglutide Gets Shut Down

The FDA resolved the semaglutide shortage, removed it from the Drug Shortage List, and sent thousands of warning letters to compounding pharmacies. Courts issued temporary restraining orders. Hims sued the FDA. Litigation is ongoing. But the direction is clear: compounded semaglutide's days as a guaranteed revenue stream are numbered.

If your brand depends on compounded GLP-1s for 50%+ of revenue, you need a GLP-1 brand diversification plan that doesn't require rebuilding your infrastructure from scratch. The good news: the intake, encounter, Rx, pharmacy routing, delivery, and refill pipeline you already run for GLP-1s applies to every other DTC Rx vertical. A DTC Rx vertical pivot to men's health, HRT, or longevity is a configuration change, not a rebuild. The pipeline is the same. The product mapping changes.

The Regulatory Reality for Compounded GLP-1s in 2026

• FDA position: Semaglutide is no longer in shortage. Compounding pharmacies should stop producing compounded versions within the transition period. The FDA considers compounded semaglutide 'essentially a copy' of a commercially available drug.
• Industry pushback: The Outsourcing Facilities Association and individual compounders have filed lawsuits. Several federal courts issued temporary restraining orders allowing continued compounding. Hims filed a separate lawsuit challenging the shortage determination.
• Current status (early 2026): Litigation is active. Some compounding continues under court protection. But no operator should build a 3-year plan assuming compounded semaglutide will remain available.
• Novo Nordisk: Aggressively pursuing legal action against compounders with cease-and-desist letters and lawsuits. They have the resources to sustain this pressure indefinitely.
• What happens to 3.7 million patients: Many will transition to brand-name Wegovy or Ozempic (at $1,000-1,300/month). Many will churn. The brands that retain them are the ones that offer alternative treatment pathways.

The Compounded Semaglutide Alternatives: Verticals You Can Enter in 30 Days

The question most GLP-1 operators ask is: if compounded semaglutide is restricted, what do I offer patients instead? The answer is not a single compounded semaglutide alternative. It is a portfolio of verticals that reactivate your existing compounding pharmacy relationships and serve many of the same patients. Every vertical below uses the same prescription commerce pipeline your GLP-1 brand already runs. The infrastructure doesn't change. You configure new products, connect to appropriate pharmacy partners, update your clinical protocols, and launch.

Men's Health: ED, Hair Loss, TRT

A $4-5 billion DTC market. Sildenafil and finasteride are non-controlled, prescribable via async telehealth, and available through the same compounding pharmacies you already work with. Compounded chewable ED tablets and topical finasteride/minoxidil combinations use the same fulfillment pipeline as your GLP-1 shipments. Customer acquisition costs are $80-300 depending on channel. Subscriptions run $15-90/month.

TRT (testosterone) is higher complexity (Schedule III, requires video consult and labs) but also higher LTV ($99-199/month, 24-60 month average lifetime). If your brand already has DEA-aware infrastructure, TRT is a natural extension.

Women's HRT and Bioidentical Hormones

55 million American women (per NAMS estimates) are peri- or postmenopausal. Only 15% receive HRT. The DTC menopause market is $2-4 billion and growing 25-35% annually. Compounded bioidentical HRT (custom estradiol, progesterone, testosterone, DHEA formulations) requires the same compounding pharmacy relationships you already have for GLP-1s. If your compounding partner makes semaglutide, they almost certainly compound hormones too.

Subscription value is high: $100-250/month for comprehensive BHRT. Patient lifetime is 18-48 months. And critically, HRT compounding is not under the same FDA pressure as GLP-1 compounding because there is no 'shortage resolution' issue. Bioidentical hormone combinations are patient-specific formulations, not copies of a commercially available product.

Prescription Skincare

Compounded tretinoin subscriptions at $25-50/month. The same compounding pharmacies, the same subscription billing, the same refill automation. Curology built an estimated $200-300 million business on this model. The regulatory environment is the simplest of any Rx vertical: no controlled substances, async telehealth in all states, minimal lab requirements.

Longevity Prescriptions

Rapamycin, metformin, NAD+, sermorelin. The fastest-growing DTC Rx vertical, estimated at 40-60% annually based on industry projections. Higher subscription value ($200-500/month) with longer patient lifetimes. Rapamycin and metformin are non-controlled generics. NAD+ and sermorelin are compounded. This vertical has the highest revenue potential per patient but requires more clinical depth (labs, biomarker tracking, dose adjustments).

Sleep and Gut Health

Trazodone for sleep ($20-35/month) and low-dose naltrexone for gut health and inflammation ($30-60/month). Both are non-controlled. LDN requires compounding (standard 50mg naltrexone compounded down to 1.5-4.5mg), so your compounding pharmacy relationships apply directly. These are natural adjacencies: many GLP-1 patients also have sleep issues and gut health concerns, making them easy cross-sells to your existing patient base.

How to Execute the DTC Rx Vertical Pivot

Week 1: Clinical Protocols and Pharmacy Confirmation

• Work with your medical director to create prescribing protocols for 1-2 new verticals
• Confirm your compounding pharmacy partners can fulfill the new product categories (they almost certainly can)
• Confirm your provider network is licensed and willing to prescribe in the new categories
• Update intake questionnaires for the new verticals

Week 2: Infrastructure Configuration

• Configure new product SKUs in your platform (product name, dosage options, pricing, pharmacy routing rules)
• Set up new intake flows for each vertical
• Build automation sequences for the new verticals (onboarding, refill reminders, follow-up scheduling)
• Update your site and checkout to offer the new products

Week 3: Soft Launch to Existing Patients

• Email your existing patient base about the new offerings. Your GLP-1 patients already trust your brand. They are the highest-conversion audience for your new verticals.
• Offer existing patients a discount on their first month of a new product (cross-sell economics are dramatically better than new patient acquisition)
• Monitor the end-to-end flow for each new vertical: intake, provider review, pharmacy fulfillment, delivery, refill

Week 4+: External Marketing

• Launch paid acquisition for the new verticals independently
• Update SEO content to target new vertical keywords
• Build content (blogs, social, email) around the new product categories
• Track unit economics per vertical and double down on the highest-performing ones

The Revenue Math: Diversification vs Concentration

A GLP-1 brand doing $100K/month with 100% concentration in compounded semaglutide is one FDA ruling away from zero revenue. A brand doing $100K/month across four verticals (GLP-1, men's health, HRT, skincare) loses 25% if GLP-1 compounding gets shut down. The remaining 75% continues growing.

• Scenario A (concentrated): $100K/month from GLP-1. FDA shuts down compounding. Revenue drops to $0-20K/month (only patients who switch to brand-name). Recovery takes 6-12 months.
• Scenario B (diversified): $40K GLP-1 + $25K men's health + $20K HRT + $15K skincare. FDA shuts down compounding. Revenue drops to $60-65K/month. You've already built the acquisition channels for the other verticals. Recovery takes 30-60 days.

What Your Compounding Pharmacy Partner Already Makes

Most 503A and 503B compounding pharmacies that produce semaglutide also compound all of the following. Ask your existing pharmacy partner about adding these products:

• Bioidentical hormones: estradiol, progesterone, testosterone (all strengths and forms)
• Skincare: tretinoin, azelaic acid, niacinamide, hydroquinone combinations
• ED medications: sildenafil and tadalafil chewables, sublingual troches
• Hair loss: topical finasteride/minoxidil combinations
• Longevity: NAD+ injectable, sermorelin, low-dose naltrexone
• Sleep: compounded trazodone (though generic tablets are usually sufficient)

Your pharmacy relationship is the asset. The specific compound they mix is the variable. Redirecting capacity from semaglutide to other products is operationally straightforward for most compounders.